Obtaining identified the palmitoylation motif of APLNR, we designed a brief substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This competitive peptide, which targets the APLNR palmitoylation website together with morphine, can inhibit the development of NCP, which includes pain incidence, microglial activation, and inflammatory variable release https://jaidenefczt.wikimidpoint.com/3942906/getting_my_block_pain_receptors_with_proleviate_to_work